60 Degrees Pharmaceuticals (SXTP) stock underwent a massive rally on Thursday after the specialty pharmaceutical company announced a partnership with Runway Health. This agreement will have the two work together to expand pre-departure access to ARAKODA for the prevention of malaria among international travelers. This plan will utilize Runway Health’s travel medicine platform.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
60 Degrees Pharmaceuticals and Runway Health will start their partnership on April 2, 2026. At this time, users of Runway Health’s direct-to-patient telehealth platform will be able to receive ARAKODA, which is the only broad-spectrum, once-weekly prescription malaria prevention available in the U.S.
Malaria prevention is an important topic for travelers heading to countries suffering from the endemic. If contracted from the Anopheles mosquito and left untreated, malaria can progress to severe malaria, which is often fatal.
60 Degrees Pharmaceuticals Stock Movement Today
60 Degrees Pharmaceuticals stock was up 168% in pre-market trading on Thursday, following a slight dip yesterday. The stock has decreased 1.62% year-to-date and 88.62% over the past 12 months.
With today’s news came heavy trading of SXTP stock, as more than 92 million shares changed hands, compared to a three-month daily average trading volume of about 200,000 units.
Is 60 Degrees Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for 60 Degrees Pharmaceuticals is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average SXTP stock price target of $4.40, representing a potential 120% upside for the shares.
